Prime Medicine, INC Form 4 insider transactions

Prime Medicine, Inc. Director Jeffrey D. Marrazzo was granted 55,000 stock options with an exercise price of $1.32, vesting by June 2026 or the next annual meeting.

Prime Medicine, Inc. announced that Director and 10% Owner Robert Nelsen was granted 55,000 stock options with an exercise price of $1.32, vesting by June 2026 or the next annual meeting.

Prime Medicine, Inc. Director Michael Aaron Kelly was granted 55,000 stock options with an exercise price of $1.32, vesting by June 2026 or the next annual meeting.

Kaye Foster-Cheek, a Director at Prime Medicine, Inc., was granted 55,000 stock options with an exercise price of $1.32, vesting by June 2026 or the next annual meeting.

Prime Medicine, Inc. Director Wendy Chung was granted 55,000 stock options with an exercise price of $1.32, set to vest by June 2026 or the next annual meeting.

Prime Medicine, Inc. Director Thomas Cahill was granted 55,000 stock options with an exercise price of $1.32, vesting by June 2026 or the next annual meeting.

Richard Brudnick, Chief Business Officer of Prime Medicine, Inc., purchased 20,000 shares of common stock at a price of $1.1895 per share on May 20, 2025.

Ann L. Lee, Chief Technical Officer of Prime Medicine, Inc., purchased 100,000 shares of common stock at $1.13 per share on May 21, 2025.

Prime Medicine's CEO, Allan Reine, recently purchased 125,000 shares of the company's common stock.

Jeffrey D. Marrazzo, a director at Prime Medicine, Inc., acquired stock options for 800,000 shares of common stock on May 19, 2025.

Prime Medicine's CEO, Allan Reine, was granted 2,000,000 stock options on May 19, 2025, according to a Form 4 filing.

Prime Medicine's CFO, Allan Reine, acquired 75,000 shares of company stock on May 8, 2025, following the achievement of a performance milestone related to a previously granted stock option.

Keith Michael Gottesdiener, a director and officer at Prime Medicine, Inc., acquired 100,000 shares of common stock via stock option vesting after a performance milestone was met.

Ann Lee, Chief Technical Officer of Prime Medicine, Inc., acquired 80,416 shares of common stock due to the vesting of a stock option following the achievement of a performance milestone.

Keith Michael Gottesdiener, President and CEO of Prime Medicine, Inc., acquired 500,000 stock options on February 28, 2025, according to a Form 4 filing with the SEC.

Carman Alenson, SVP, Finance and Chief Accounting Officer of Prime Medicine, Inc., was granted stock options for 90,500 shares on February 27, 2025.

Meredith Goldwasser, SVP of Strategy & Corporate Operations at Prime Medicine, Inc., reports the acquisition of 90,500 stock options exercisable at $2.42, vesting monthly from February 27, 2025.

Jeremy Duffield, Chief Scientific Officer of Prime Medicine, Inc., acquired 275,000 stock options on February 27, 2025, at an exercise price of $2.42.

Ann L. Lee, Chief Technical Officer of Prime Medicine, Inc., was granted stock options to purchase 275,000 shares of common stock.

Richard Brudnick, Chief Business Officer of Prime Medicine, Inc., acquired 225,000 stock options on February 27, 2025, according to a Form 4 filing with the SEC.

Chief Financial Officer Allan Reine of Prime Medicine, Inc. reports the acquisition of stock options.

A Prime Medicine director, Keith Michael Gottesdiener, acquired 100,000 shares through the vesting of a stock option.

A Prime Medicine executive, Richard Brudnick, exercised stock options for 19,300 shares after a performance milestone was met.

Prime Medicine's Chief Financial Officer, Allan Reine, acquired 75,000 shares of common stock through the vesting of a stock option due to the achievement of a performance milestone.

Keith Michael Gottesdiener, a director and officer at Prime Medicine, reported the transfer of shares to a family trust for estate planning purposes.

Jeffrey D. Marrazzo, a director of Prime Medicine, Inc., acquired stock options for 45,000 shares on June 12, 2024.

Director David P. Schenkein acquired 45,000 stock options in Prime Medicine, Inc. on June 12, 2024.

Director Robert Nelsen acquired 45,000 stock options in Prime Medicine, Inc. on June 12, 2024, vesting fully by June 12, 2025, or the next annual meeting.

Director Michael Aaron Kelly acquired stock options for 45,000 shares of Prime Medicine, Inc. on June 12, 2024.

Director Kaye I. Foster-Cheek acquired 45,000 stock options in Prime Medicine, Inc. on June 12, 2024.